Cancer is soon expected to surpass heart disease as the number one cause of mortality. This year, in the USA alone, more than 2 million new cancer diagnoses are expected and more than 610,000 will die from cancer. Globally more than 20 million new cancer diagnoses and nearly 10 million deaths are expected this year. While enormous progress is being made in the treatment of advanced cancer, the most effective approach to better outcomes may be earlier detection of cancers. Compared to early diagnosis (Stages I and II) which can be cured completely with excision, delayed diagnosis (Stage IV) is associated with very poor outcomes and very expensive treatment options. This webinar will explore how precision epigenomics has created an assay that detects abnormally methylated circulating tumor DNA using a simple blood draw. The EPISEEK assay with its patented probes and proprietary classifier can detect the most aggressive cancers with high sensitivity and specificity.
Speaker Name and Credentials: Richard A. Bernert, M.D.
